Breaking News

BARDA Contracts Just – Evotec to Optimize Biomanufacturing of Antibodies Against Filovirus

Just – Evotec Biologics will use its validated technology platforms to perform molecular optimization, cell line development, and manufacturing process development for two antibodies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Just – Evotec Biologics, Inc. has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to advance manufacturing optimization for a monoclonal antibody cocktail targeting filovirus diseases, including Ebola virus (EBOV) and Sudan virus (SUDV). The multi-year program award, valued at up to $10 million if all options are activated, aims to support BARDA’s efforts to support the development ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters